Who
Andrea DiFabio
Chief Legal Officer
Company insider
Files Form 4 as: Chief Legal Officer, Xenon Pharmaceuticals; EVP, Chief Legal Officer, Bioverativ.
In numbers
- Trades disclosed
- 51
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $462K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 14 Feb 2017
- Last trade
- 13 Mar 2026
- Last filed
- 13 Mar 2026
Companies traded
Activity over time
1 Mar – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 13 Mar 2026filed 13 Mar 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $74K1,342 at $55.23 | filing |
| 13 Mar 2026filed 13 Mar 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $74K1,342 at $55.23 | filing |
| 12 Mar 2026filed 13 Mar 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —3,750 | filing |
| 12 Mar 2026filed 13 Mar 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,750 at $0.00 | filing |
| 12 Mar 2026filed 13 Mar 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,750 at $0.00 | filing |
| 12 Mar 2026filed 13 Mar 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —3,750 | filing |
| 10 Mar 2026filed 11 Mar 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $157K2,607 at $60.11 | filing |
| 10 Mar 2026filed 11 Mar 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $157K2,607 at $60.11 | filing |
| 9 Mar 2026filed 11 Mar 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —7,500 | filing |
| 9 Mar 2026filed 11 Mar 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,500 at $0.00 | filing |
| 9 Mar 2026filed 11 Mar 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,500 at $0.00 | filing |
| 9 Mar 2026filed 11 Mar 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,500 at $0.00 | filing |
| 9 Mar 2026filed 11 Mar 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,500 at $0.00 | filing |
| 9 Mar 2026filed 11 Mar 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —7,500 | filing |
| 9 Jan 2026filed 9 Jan 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 9 Jan 2026filed 9 Jan 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 9 Jan 2026filed 9 Jan 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 9 Jan 2026filed 9 Jan 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 12 Mar 2025filed 13 Mar 2025 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 12 Mar 2025filed 13 Mar 2025 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
News
Contrasting Xenon Pharmaceuticals (NASDAQ:XENE) and United Therapeutics (NASDAQ:UTHR)XENE · dailypolitical.com · 18 Oct 2026Head to Head Survey: Xenon Pharmaceuticals (NASDAQ:XENE) vs. United Therapeutics (NASDAQ:UTHR)XENE · themarketsdaily.com · 12 Oct 2026
0 headlines in the last 90 days name Andrea DiFabio; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.